Racura Oncology 

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments in Australia. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors. It also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, the company investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein. It has collaborations with Astex, MD Anderson, Sheba City of Health, University of North Carolina School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Coronado Resources Limited. Race Oncology Limited was incorporated in 2011 and is headquartered in Sydney, Australia.